Barclays PLC Has $1.16 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Barclays PLC decreased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,211 shares of the company’s stock after selling 9,064 shares during the quarter. Barclays PLC owned about 0.31% of iTeos Therapeutics worth $1,155,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ITOS. nVerses Capital LLC boosted its position in shares of iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the last quarter. Point72 DIFC Ltd acquired a new position in iTeos Therapeutics in the third quarter valued at about $31,000. China Universal Asset Management Co. Ltd. boosted its holdings in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after buying an additional 2,646 shares during the last quarter. Quest Partners LLC grew its position in shares of iTeos Therapeutics by 914.7% during the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after buying an additional 9,934 shares during the period. Finally, US Bancorp DE increased its stake in shares of iTeos Therapeutics by 206.0% in the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock valued at $123,000 after acquiring an additional 8,129 shares during the last quarter. 97.16% of the stock is owned by institutional investors.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now owns 65,429 shares of the company’s stock, valued at $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ITOS. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Friday. Wells Fargo & Company reduced their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Stock Up 0.5 %

Shares of NASDAQ:ITOS opened at $7.80 on Tuesday. The firm has a market cap of $284.97 million, a price-to-earnings ratio of -2.48 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12 month low of $7.09 and a 12 month high of $18.75. The company’s fifty day simple moving average is $8.11 and its 200 day simple moving average is $11.69.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.18) by $0.13. Research analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.